Sub Heading

Clinical Trials Details

A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphoma

IRB Protocol Number
Amgen 20210098 (FORTITUDE-102)

Clinical Trial Categories

  • Gastric Cancer
Contact
Clinical Trials at 910-715-2200
How to Participate

Eligibility: Men and women age 18 and older with unresectable, locally advanced, or metastatic histologically documented gastric or GEJ adenocarcinoma with PDL-1 positive disease.

Contact Us

For more information on participating in a clinical trial, contact us at 910-715-2200 or talk to your doctor.